People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AiVita Biomedical, Inc. | — | Biotechnology | Series B | $39.5M | $95.6M | 2018 |
Ungbae B. Lee at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ungbae B. Lee on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alexander B. Suh | 1 | 3 |
| Scott Burell | 1 | 3 |
| Alexander Suh | 1 | 3 |
| Hans Keirstead | 1 | 3 |
| Philippe Schaison | 1 | 3 |
| Paul Jenkinson | 1 | 2 |
| Matthew Katz | 1 | 2 |
| Hans S. Keirstead | 1 | 2 |
| CHRIS FIBIGER | 1 | 2 |
| Ed B. Inal | 1 | 1 |
| Susan B. Bloomfield | 1 | 1 |
| Gabriel S. Nistor | 1 | 1 |
| Ungbae Lee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.